Mesoblast Files New Issue and Director Interest Notices
Ticker: MEOBF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, director-dealings, new-issue
TL;DR
MESO filed new issue and director interest notices on 9/12/25.
AI Summary
On September 12, 2025, Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y) with the Australian Securities Exchange. The filing is a Form 6-K report for the month of September 2025, indicating the company's ongoing reporting obligations.
Why It Matters
This filing provides transparency regarding Mesoblast's recent share issuances and changes in director holdings, which can be important for investors monitoring company activity and insider transactions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of new issue announcements and director interest changes, not indicating significant financial distress or major strategic shifts.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- September 12, 2025 (date) — Filing date of announcement
- Australian Securities Exchange (company) — Exchange where filings were made
FAQ
What type of announcements did Mesoblast Limited file on September 12, 2025?
Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y).
Where were these announcements filed?
The announcements were filed with the Australian Securities Exchange.
What is the Commission File Number for Mesoblast Limited?
The Commission File Number for Mesoblast Limited is 001-37626.
Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
What is the primary business of Mesoblast Limited?
Mesoblast Limited is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Filing Stats: 219 words · 1 min read · ~1 pages · Grade level 17.8 · Accepted 2025-09-15 07:45:39
Filing Documents
- form6-kxpressreleasecoverf.htm (6-K) — 15KB
- exhibit991drggeorgeappen.htm (EX-99.1) — 5KB
- exhibit991drggeorgeappen001.jpg (GRAPHIC) — 136KB
- exhibit991drggeorgeappen002.jpg (GRAPHIC) — 116KB
- exhibit991drggeorgeappen003.jpg (GRAPHIC) — 56KB
- 0001345099-25-000074.txt ( ) — 446KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated September 12, 2025 INDEX TO EXHIBITS Item 99.1 Appendix 3Y of Mesoblast Ltd, dated September 12, 2025.